Payment overview · 2025
General Payments
$97.14
5 reported records · 4 companies
Healthcare provider profile · identity verified
Jack Kendrick, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PRESTONSBURG, KY · NPI 1255489415
Verified facts
What the public records show
CMS Open Payments records show Jack Kendrick, MD received $97.14 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 40.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.05 | 40.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.63 | 27.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $15.86 | 16.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.60 | 16.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.14 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
101 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 748 | 175 |
| Furosemide | Furosemide | 674 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 669 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 531 | 84 |
| Eliquis | Apixaban | 511 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 510 | 116 |
| Omeprazole | Omeprazole | 509 | 113 |
| Gabapentin | Gabapentin | 484 | 66 |
| Lisinopril | Lisinopril | 384 | 98 |
| Potassium Chloride | Potassium Chloride | 334 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 83 |
| Clopidogrel | Clopidogrel Bisulfate | 310 | 63 |
| Metformin Hcl | Metformin Hcl | 299 | 70 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 298 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 280 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 269 | 60 |
| Prednisone | Prednisone | 264 | 116 |
| Losartan Potassium | Losartan Potassium | 262 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 68 |
| Alprazolam | Alprazolam | 250 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 56 |
| Diazepam | Diazepam | 231 | 31 |
| Trazodone Hcl | Trazodone Hcl | 225 | 40 |
| Lactulose | Lactulose | 215 | 52 |
| Montelukast Sodium | Montelukast Sodium | 181 | 38 |
| Carvedilol | Carvedilol | 178 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 169 | 39 |
| Simvastatin | Simvastatin | 166 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 159 | 37 |
| Ondansetron Odt | Ondansetron | 158 | 22 |
| Sertraline Hcl | Sertraline Hcl | 150 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 30 |
| Meloxicam | Meloxicam | 146 | 35 |
| Allopurinol | Allopurinol | 143 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 118 | 21 |
| Famotidine | Famotidine | 117 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 117 | 23 |
| Sucralfate | Sucralfate | 115 | 23 |
| Mirtazapine | Mirtazapine | 112 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 22 |
| Clonazepam | Clonazepam | 102 | 13 |
| Levetiracetam | Levetiracetam | 102 | 22 |
| Linzess | Linaclotide | 101 | 23 |
| Buspirone Hcl | Buspirone Hcl | 100 | 25 |
| Azithromycin | Azithromycin | 98 | 70 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 19 |
| Donepezil Hcl | Donepezil Hcl | 95 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 23 |
| Mounjaro | Tirzepatide | 94 | 14 |
| Cefuroxime | Cefuroxime Axetil | 90 | 72 |
| Finasteride | Finasteride | 90 | 20 |
| Pregabalin | Pregabalin | 88 | 14 |
| Ezetimibe | Ezetimibe | 86 | 17 |
| Farxiga | Dapagliflozin Propanediol | 86 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 23 |
| Ozempic | Semaglutide | 81 | 17 |
| Nystatin | Nystatin | 80 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 34 |
| Divalproex Sodium | Divalproex Sodium | 79 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 77 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 76 | 19 |
| Tramadol Hcl | Tramadol Hcl | 73 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 72 | 13 |
| Bumetanide | Bumetanide | 71 | 18 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 70 | 41 |
| Baclofen | Baclofen | 69 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 65 | 13 |
| Celecoxib | Celecoxib | 61 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 14 |
| Xarelto | Rivaroxaban | 60 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 44 |
| Clonidine Hcl | Clonidine Hcl | 58 | 14 |
| Lorazepam | Lorazepam | 58 | suppressed |
| Ibuprofen | Ibuprofen | 57 | 21 |
| Nystop | Nystatin | 56 | 24 |
| Methocarbamol | Methocarbamol | 54 | 23 |
| Fluconazole | Fluconazole | 53 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | suppressed |
| Levofloxacin | Levofloxacin | 51 | 38 |
| Atenolol | Atenolol | 50 | suppressed |
| Glipizide | Glipizide | 49 | suppressed |
| Latanoprost | Latanoprost | 49 | suppressed |
| Spironolactone | Spironolactone | 49 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 43 |
| Santyl | Collagenase Clostridium Hist. | 47 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 47 | suppressed |
| Jardiance | Empagliflozin | 46 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 19 |
| Amoxicillin | Amoxicillin | 44 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 12 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 11 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 42 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 29 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 26 |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 33 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 24 |
| Meclizine Hcl | Meclizine Hcl | 31 | 12 |
| Midodrine Hcl | Midodrine Hcl | 31 | 13 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 17 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Humalog | Insulin Lispro | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | 12 |
| Lidocaine Hcl | Lidocaine Hcl | 22 | 16 |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 20 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Victoza 3-Pak | Liraglutide | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | 11 |
| Ibu | Ibuprofen | 18 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Verapamil Er Pm | Verapamil Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 14 | 12 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Klayesta | Nystatin | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.14 · 5 records | ABBVIE INC. | AREXVY, FANAPT, Flector, HETLIOZ, Licart, SHINGRIX, Tirosint, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error